A.O. Ospedale Maggiore di Lodi Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2013
NCT02076594
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

A.O. Ospedale Maggiore di Lodi, Oncologia | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, UOS Milano, Italy, 20122 | IRCCS Ca' Granda Osp. Maggiore Policlinico | NICU. Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano, Milan, Italy, 20122 | OSPEDALE MAGGIORE LODI

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Cataract (Phase 4)

Communicable Diseases (Phase 2)

Coronavirus Infections (Phase 2)

Dyspnea (Phase 2)

Eye Infections (Phase 4)

Infections (Phase 2)

Muscular Dystrophies (Phase 2)

Muscular Dystrophy, Duchenne (Phase 2)

Nephrosis (Phase 2)

Nephrotic Syndrome (Phase 2)

Pneumonia (Phase 2)

Pneumonia, Viral (Phase 2)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Scleroderma, Diffuse (Phase 4)

Scleroderma, Localized (Phase 4)

Scleroderma, Systemic (Phase 4)

Severe Acute Respiratory Syndrome (Phase 2)

Shock (Phase 3)

Shock, Septic (Phase 3)

Stomach Neoplasms (Phase 3)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 21
  • # of Trial APIs: 27